Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 12, 2016

Primary Completion Date

April 9, 2019

Study Completion Date

March 8, 2020

Conditions
Acute Graft vs Host Disease
Interventions
DRUG

Recombinant Human Interleukin-22 IgG2-Fc (F-652)

IV infusion of reconstitution lyophilized F-652.

DRUG

Systemic Corticosteroids

Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.

Trial Locations (3)

10065

MSKCC, New York

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

EVIVE Biotechnology

INDUSTRY